Thus, in this study, we sought to evaluate the effectiveness of RBCEVs in delivering RIG‐I agonists, including an immunomodulatory RNA (immRNA) and a bi‐functional ASO for anti‐cancer therapy. This evidence concerns the gene RIGI and cancer.